New Study from Tufts Center for the Study of Drug Development Establishes Benchmarks for Vendor Qualification Process
14 nov. 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- While more than 90% of all contract vendor assessments conducted by drug sponsors ultimately lead to vendors being qualified to provide services, large...
Cancer Drugs Now Account for 27% of all New Drug Approvals in the U.S., According to Tufts Center for the Study of Drug Development
03 sept. 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a...
Growth in Rare Disease R&D Is Challenging Development Strategy and Execution, According to Tufts Center for the Study of Drug Development
09 juil. 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, July 09, 2019 (GLOBE NEWSWIRE) -- Rare disease drug development, which now accounts for nearly one-third of all drugs in active R&D worldwide, presents scientific and operational...
Adoption of Artificial Intelligence Is High Across Pharmaceutical Industry, According to Tufts Center for the Study of Drug Development
07 mai 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, May 07, 2019 (GLOBE NEWSWIRE) -- The pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk assessment and...
Drug Development Outsourcing Outpaces Internal Spending but Remains Tactical and Reactive, According to Tufts Center for the Study of Drug Development
05 mars 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Drug sponsors spend more on contract research organizations (CROs) to help develop new medicines than they do on internal staff and infrastructure, but...
U.S. Continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise, According to the Tufts Center for the Study of Drug Development
08 janv. 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also...
Global Biotech Product Development Expected to Continue Its Multi-Decade Surge, According to the Tufts Center for the Study of Drug Development
13 nov. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- With more than 500 Phase III clinical trials now underway for biotech products worldwide, the multi-decade surge in new biopharmaceutical approvals is...
Study Finds Seniors with Muscle Loss Due to Sarcopenia Improve with New Prescription Protocol
01 oct. 2018 13h55 HE
|
AstaMed
Seattle, WA, Oct. 01, 2018 (GLOBE NEWSWIRE) -- AstaMed, a pioneer in the field of natural sarcopenia treatment options, announced the results of the randomized, double-blind placebo-controlled study...
CNS Drugs Take 20% Longer to Develop and 38% Longer to Approve vs. Non-CNS Drugs, According to the Tufts Center for the Study of Drug Development
11 sept. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Developing drugs to treat central nervous system (CNS) disorders on average required 20% more time than other drugs that won marketing approval in the...
Rising Protocol Complexity Is Hindering Performance while Driving Up Cost of Clinical Trials, According to the Tufts Center for the Study of Drug Development
17 juil. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, July 17, 2018 (GLOBE NEWSWIRE) -- Rising protocol complexity is hindering clinical trial performance and efficiency, and helping to drive up the cost of developing new drugs, according to a...